The new Dogma meets Thomas Kuhn’s definition of a paradigm shift. The DNA/RNA Dogma is sufficiently unprecedented to attract ...

A study led by the University of Barcelona and the Spanish National Research Council's Institute for Advanced Chemistry of ...

Welcome back to Genomics Week in Brief – your number one stop for all the latest and greatest genomics news (and more)!

A study led by the University of Barcelona and the Spanish National Research Council's Institute for Advanced Chemistry of Catalonia (IQAC - CSIC) presents a new therapeutic tool capable of inhibiting ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

This important study by Bi and colleagues employed a clever genetics screen to uncover the role of the GidB rRNA methylase in translation fidelity, under certain conditions, in Mycobacterium smegmatis ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

Poseida Therapeutics Inc. is being bought out for $1.5 billion by partner Roche Holdings Inc. to allogeneic CAR T therapies to treat hematologic malignancies. The two companies began their ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...

Financially, Verve has a market cap of $475mn, cash balance of $540mn, and a cash runway of 7-8 quarters. Find out my ...

The CRISPR-SCD trial is the first clinical attempt to use a non-viral delivery approach to directly correct the sickle cell ...